Literature DB >> 7189453

Pergolide, a potent long-acting dopamine-receptor agonist.

L Lemberger, R Crabtree, J T Callaghan.   

Abstract

After single doses (100 to 400 microgram orally), pergolide, a synthetic ergot, reduced basal plasma prolactin levels in normal subjects in a dose-related manner. This effect persisted for more than 24 hr. Multiple doses of pergolide (150 to 250 microgram daily for 7 days) resulted in a plasma prolactin decrease of more than 80%. A single dose of pergolide (150 microgram orally) suppressed plasma prolactin and abolished the plasma prolactin diurnal rhythm, i.e., suppression of sleep-induced elevation in plasma prolactin during a 40-hr period. Perphenazine (5 mg intramuscularly)-induced plasma prolactin elevation was inhibited by pergolide; the effect was dose dependent. After single or multiple doses, pergolide had no effect on plasma follicle-stimulating hormone, luteinizing hormone, cortisol, growth hormone, and thyroid-stimulating hormone. Pergolide appears to have specificity at the pituitary level for the dopamine receptors that mediate prolactin secretion.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7189453     DOI: 10.1038/clpt.1980.91

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  8 in total

1.  A dose rising study of the safety and effects on serum prolactin of SK&F 101468, a novel dopamine D2-receptor agonist.

Authors:  G Acton; C Broom
Journal:  Br J Clin Pharmacol       Date:  1989-10       Impact factor: 4.335

Review 2.  Clinical pharmacokinetics of anti-parkinsonian drugs.

Authors:  J M Cedarbaum
Journal:  Clin Pharmacokinet       Date:  1987-09       Impact factor: 6.447

Review 3.  Drug-induced changes in prolactin secretion. Clinical implications.

Authors:  K Hell; H Wernze
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Nov-Dec

Review 4.  Pergolide. A review of its pharmacological properties and therapeutic potential in Parkinson's disease.

Authors:  H D Langtry; S P Clissold
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

5.  Pergolide therapy in Parkinson's disease.

Authors:  P Jeanty; M Van den Kerchove; A Lowenthal; H De Bruyne
Journal:  J Neurol       Date:  1984       Impact factor: 4.849

6.  Mesulergine and pergolide in previously untreated Parkinson's disease.

Authors:  A Wright; A J Lees; G M Stern
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-04       Impact factor: 10.154

7.  Reduction in size of prolactin-secreting tumours in men treated with pergolide.

Authors:  P Kendall-Taylor; K Hall; D G Johnston; R W Prescott
Journal:  Br Med J (Clin Res Ed)       Date:  1982-08-14

8.  Network neighbors of drug targets contribute to drug side-effect similarity.

Authors:  Lucas Brouwers; Murat Iskar; Georg Zeller; Vera van Noort; Peer Bork
Journal:  PLoS One       Date:  2011-07-13       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.